InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States
Tel Aviv, Israel – February 24, 2021 – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart...
This is my next BNGO! please invest money you are willing to lose and i am not a financial advisor.
see comprehensive DD in reddit.
see the recent news.
-aiming for 10 billion market share in carotid stent
-partnership in china where stroke is #1 cause of death
-their stent is innovative and they have patents
-innovative israeli company and...
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime...
It may take long time to achieve the goal but indicators showing volume moving better
InspireMD, Inc. is a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease.
Acquired a pretty sweet position on the turn here, now set up for, at most, 3 target take-profit zones. This is looking to be a speedy trade, from the symmetry, geometry, and highly harmonic set-ups on this stock chart. Check it out and load up or reload around here!
InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering
$NSPR today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of $18 million (or $20.7 million if the underwriters exercise their option to purchase additional securities) prior to deducting underwriting discounts and estimated offering...
Now like you and many others I'm shocked by NSPR price action, so what could have caused it? Well theres one and that was the FDA IDE approval, yet today was ann that they got the full FDA IDE approval green light.
-Got FDA IDE approval in the US today
-Last week they where at LD Micro 500 they gave us some company insights
1: Theres already sales in Brazil...
Okay I'm gonna start off with the news
-NSPR beat earnings by 44%, yet still losing money. It has been making more money due to its past performance and not losing as much. We can project that they might be profitable next year.
-Their offering that was held in June came out that it was so they can remain compliant with the exchange. That Friday they have...